ArticleInvestigative ophthalmology & visual science2026
Morphological Changes in Fungal Elements and Antifungal Drug Susceptibility in an Ex Vivo Model of Fungal Keratitis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fungal keratitis is a serious eye infection that can cause irreversible vision loss. One of the causative fungal pathogens, Fusarium solani (Neocosmospora solani), shows limited susceptibility to antifungal drugs. Furthermore, differences between in vitro and clinical outcomes are encountered in some cases, complicating treatment. In this study, we compared in vitro and ex vivo antifungal susceptibility using a porcine corneal model of F. solani keratitis. Methods: An ex vivo fungal keratitis model was developed using porcine corneas, which were inoculated with F. solani and assigned to four treatment groups: natamycin (NAT), voriconazole (VRCZ), luliconazole (LLCZ), or saline (uninfected control). We compared the antifungal efficacy of each drug on day 2 to day 4 of fungal development. DNA was extracted from all corneas and used in real-time polymerase chain reaction to quantitatively assess fungal growth. Fungal morphology was examined by digital microscopy. Results: All antifungal treatment groups demonstrated antifungal activity. The NAT-treated group showed clear inhibition of fungal growth as well as fungal structural damage. The VRCZ-treated group exhibited growth inhibition; however, fungal growth persisted even after additional drug administration. The LLCZ-treated group not only suppressed fungal growth but also caused structural disruption of fungal cells after additional administration, suggesting a strong antifungal effect. Conclusions: We successfully established an ex vivo Fusarium keratitis model using porcine corneas, which enabled us to evaluate antifungal susceptibility by quantifying fungal growth and observing fungal morphological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.